Huonsen Confirms Body Fat Reduction Effects of Probiotics and Postbiotics

Applications Submitted for Individual Ingredient Recognition
Product Launch Planned After Approval in the Second Half of the Year

On July 31, Huonsen announced that it had secured body fat reduction study results through human trials of its self-developed 'Propionibacterium freudenreichii MJ2 (MJ2 Probiotics)' and the postbiotic 'Bifidobacterium longum HN001 heat-treated culture concentrate (HN001 Postbiotics)'.

Huonsen conducted separate human studies for each ingredient to verify their efficacy. Based on these results, the company has completed individual ingredient applications for recognition of their potential functionality in supporting body fat reduction. The goal is to obtain approval in the second half of this year.

The MJ2 Probiotics showed significant reduction of lower body fat in human trials. In a study of 100 overweight adults who consumed 10 billion CFUs of MJ2 Probiotics daily for 12 weeks, both lower body and overall body fat mass and fat percentage were significantly reduced compared to the placebo group.

HN001 Postbiotics demonstrated improvement in upper body and abdominal fat. In a study of 100 overweight adults who consumed 650 mg of HN001 Postbiotics daily for 12 weeks, reductions in trunk and total body fat mass and fat percentage were statistically significant compared to the placebo group.

For both ingredients, there was no significant change in body weight excluding fat before and after supplementation.

Huonsen plans to introduce a next-generation range of products supporting body fat reduction by utilizing both ingredients in combination, once the individual ingredient registrations are completed.

This content was produced with the assistance of AI translation services.